Quotes

Back To Menu

Indoco Remedies Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Invest

20 Dec 2024 | 04:14 PM

339.95
5.10 (1.52%)

Independent Research

Reuters

We bring you Independent research views from famous names like Reuters and theScreeners to help improve your investing results and create wealth

Performance parameters

  • Earnings Revision Trend

    Analysts positive since 28-Apr-2020

    Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 28-Apr-2020 at a price of 238.55.

  • Valuation Rating

    Fairly priced

    Based on its growth potential and our own criteria, at its current price the stock is fairly valued.

  • MT Tech Trend

    Trend positive since 03-Apr-2020

    The forty day Medium Term Technical Trend is positive since 03-Apr-2020. The confirmed Technical Reverse point (Tech Reverse - 1.75%) is 225.292.

  • 4W REL Performance

    Under pressure (vs. SENSEX30)

    The four week relative underperformance versus SENSEX30 is -2.470.

Risk parameters

  • Risk Zone

    Moderate

    The stock has been on the moderate-sensitivity level since 24-Dec-2019.

  • Bear Market

    Average sensitivity to market corrections

    On average, the stock is likely to decline with the index.

  • Bad News

    Slight market sanction in case of specific pressure

    When the stock's pressure is specific, the market sanction on average is 384%.

  • Beta

    98 Average sensitivity to SENSEX30

    For 1% of index variation, the stock varies on average by 98%.

  • Correlation

    0.47 Fair correlation to SENSEX30

    0.4725% of stock movements are explained by index variations.

  • Value at Risk

    Rs.56.09 The medium term value at risk is estimated at 56.09 or 0.24000%

    The value at risk is estimated at 56.09. The risk is therefore 0.24000%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.

Other parameters

  • LT Growth

    71.52 Current year to 2022 annualized estimate

    The annualized growth estimate is for the current year to 2022.

  • P/E Ratio

    16.2 Estimated PE for 2022

    The estimated PE is for the year 2022.

  • G/PE Ratio

    4.45 High discount to expected growth due to base effect

    A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).

  • Dividend Yield

    0.59% Dividend is largely covered by profits

    The twelve month estimated dividend yield represents 9.608% of earnings forecasts.

  • Global Evaluation

    Neutral

    The stock is classified in the neutral zone since 25-Feb-2020.